Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

FLUPHENAZINE (ORAL) vs RISPERIDONE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.08 [0.08, 15.46]
1 study · 25 participants
Very low

FLUPHENAZINE (ORAL) vs OLANZAPINE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3 [0.33, 27.23]
1 study · 60 participants
Very low

FLUPHENAZINE (ORAL) vs QUETIAPINE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.46 [0.05, 4.46]
1 study · 25 participants
Very low